BLA 125057/S-411

SUPPLEMENT APPROVAL

AbbVie Inc
Attention: Eric Larson
Sr. Manager, Regulatory Affairs
1 North Waukegan Rd
Dept. Pa72/Bldg. Ap30
North Chicago, IL 60064

Dear Mr. Larson:

Please refer to your Supplemental Biologics License Application (sBLA) dated and received July 13, 2018, and your amendment, submitted under section 351(a) of the Public Health Service Act for Humira (adalimumab) injection.

This Prior Approval supplemental biologics license application provides for revised package labeling for all strengths and presentations of the Humira (adalimumab) injection.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text and with the minor editorial revisions indicated in the enclosed labeling.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm), that is identical to the enclosed labeling (text for the prescribing information) and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf).

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in MS Word format that includes the changes approved in this supplemental application.
CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to the submitted carton and immediate container labels, except with the revisions listed above, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (May 2015, Revision 3). For administrative purposes, designate this submission “Final Printed Carton and Container Labels for approved BLA 125057/S-411.” Approval of this submission by FDA is not required before the labeling is used.

If you have any questions, call Andrew Shiber, Regulatory Business Process Manager, at (301) 796 - 4798.

Sincerely,

{See appended electronic signature page}

Xianghong Jing, Ph.D. for
David Frucht, M.D.
Director
Division of Biotechnology Review and Research II
Office of Biotechnology Products
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosure(s):

Content of Labeling
Carton and Container Labeling